Hsbc Holdings PLC Cuts Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Hsbc Holdings PLC reduced its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 8.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 228,030 shares of the specialty pharmaceutical company's stock after selling 22,334 shares during the quarter. Hsbc Holdings PLC owned approximately 0.41% of Supernus Pharmaceuticals worth $8,246,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Barclays PLC boosted its holdings in shares of Supernus Pharmaceuticals by 88.3% in the 3rd quarter. Barclays PLC now owns 108,788 shares of the specialty pharmaceutical company's stock worth $3,393,000 after buying an additional 51,005 shares during the last quarter. Franklin Resources Inc. raised its position in Supernus Pharmaceuticals by 7.6% in the third quarter. Franklin Resources Inc. now owns 29,981 shares of the specialty pharmaceutical company's stock worth $987,000 after acquiring an additional 2,121 shares during the period. Principal Financial Group Inc. boosted its stake in Supernus Pharmaceuticals by 5.4% in the third quarter. Principal Financial Group Inc. now owns 285,411 shares of the specialty pharmaceutical company's stock valued at $8,899,000 after acquiring an additional 14,566 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of Supernus Pharmaceuticals by 40.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 253,396 shares of the specialty pharmaceutical company's stock valued at $7,901,000 after acquiring an additional 73,118 shares during the period. Finally, Burney Co. increased its stake in shares of Supernus Pharmaceuticals by 603.4% during the 4th quarter. Burney Co. now owns 83,152 shares of the specialty pharmaceutical company's stock worth $3,007,000 after purchasing an additional 71,331 shares during the last quarter.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. Cantor Fitzgerald reiterated a "neutral" rating and issued a $36.00 price objective on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th. StockNews.com raised Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Thursday, April 17th.

Supernus Pharmaceuticals Trading Up 1.2 %

Shares of SUPN stock traded up $0.39 during trading on Friday, reaching $32.84. 359,758 shares of the company's stock traded hands, compared to its average volume of 494,997. The firm's 50-day moving average is $31.86 and its 200 day moving average is $34.98. The company has a market capitalization of $1.83 billion, a P/E ratio of 30.69 and a beta of 0.74. Supernus Pharmaceuticals, Inc. has a 1 year low of $25.53 and a 1 year high of $40.28.

Insiders Place Their Bets

In other news, VP Padmanabh P. Bhatt sold 9,477 shares of the stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total value of $376,236.90. Following the sale, the vice president now directly owns 10,149 shares of the company's stock, valued at approximately $402,915.30. This represents a 48.29 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Jonathan Rubin sold 927 shares of the business's stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $39.15, for a total transaction of $36,292.05. Following the transaction, the senior vice president now directly owns 7,853 shares of the company's stock, valued at approximately $307,444.95. This represents a 10.56 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 9.30% of the company's stock.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.